Exacis Biotherapeutics

Induced Pluripotent Stem Cells (iPSCs)
#Acquisition #allogeneic cell therapies #Cancer research #Eterna Therapeutics #Exacis Biotherapeutics #Immuno-oncology #iPSC

Eterna acquires Exacis’ allogeneic immuno-oncology platform

Eterna Therapeutics, a life science company focused on mRNA cell engineering, has acquired Exacis Biotherapeutics’ immuno-oncology platform. The acquisition will provide Eterna with a pipeline of allogeneic immuno-oncology products under development for the treatment of haematologic and solid tumours. The deal also provides Eterna with an exclusive global license to… Read More

#Business & Investment #News